Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      genOway:Revolucionando la predicción de terapias con anticuerpos en humanos con un modelo de ratón único

      genOway Logo

      News provided by

      genOway

      Feb 26, 2026, 03:15 ET

      Share this article

      Share this article


      LYON, Francia, 26 de febrero de 2026 /PRNewswire/ -- Las terapias con anticuerpos están transformando el tratamiento del cáncer, las enfermedades inflamatorias y las infecciones. Sin embargo, muchos candidatos a medicamentos prometedores fracasan en los ensayos clínicos. Un estudio publicado en Science Immunology muestra que el modelo murino genO-hFcγR de genOway permite una predicción más precisa de la eficacia y la seguridad de los anticuerpos terapéuticos.

      ¿Por qué las terapias con anticuerpos fallan en las pruebas de fase avanzada?

      Continue Reading
      genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
      genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
      genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
      genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model

      Las terapias con anticuerpos funcionan en parte uniéndose a los receptores Fcγ, proteínas presentes en las células inmunitarias que controlan funciones inmunitarias clave, como la muerte celular mediada por anticuerpos y la inflamación. Dado que estos receptores difieren entre especies, las terapias humanas probadas en ratones de laboratorio estándar arrojan resultados de eficacia poco fiables o no detectan posibles riesgos de seguridad. Estas discrepancias provocan costosos fracasos en etapas avanzadas y ralentizan el acceso de los pacientes a nuevas terapias.

      Un nuevo modelo de ratón con receptores Fcγ humanizados podría ser revolucionario

      Un nuevo estudio publicado en Science Immunology demostró que un innovador modelo murino desarrollado por genOway, genO-hFcγR, ayuda a los científicos a predecir mejor la eficacia y seguridad de los anticuerpos terapéuticos en humanos. El modelo permite a los científicos clasificar diferentes anticuerpos según su rendimiento potencial, así como medir su eficacia al atacar células inmunitarias específicas y evaluar su potencial para ralentizar la progresión de la enfermedad. Esto proporciona a los investigadores información clave para orientar las decisiones y acelerar el desarrollo de fármacos.

      Vídeo sobre el ratón genO-hFcγR: https://www.youtube.com/watch?v=H7xO-xGJV8Q

      Lea la publicación: https://www.science.org/doi/10.1126/sciimmunol.ady7328

      Un desafío científico complejo logrado mediante la colaboración internacional

      Debido a que los receptores Fcγ son diferentes entres las especies el desarrollo de este modelo exigió experiencia multidisciplinaria en genética de ratones, biología de anticuerpos e inmunología humana.

      El logro fue posible gracias a un consorcio internacional de socios biofarmacéuticos líderes, encabezado por genOway, quienes combinaron sus conocimientos para co-desarrollar y co-validar el modelo murino genO-hFcγR. Los miembros del consorcio incluyeron genOway (Francia), una compañía especializada en el desarrollo de modelos preclínicos altamente predictivos; argenx (Bélgica), pionera en ingeniería de Fc y biología de FcRn; Innate Pharma (Francia), líder en inmunoterapias basadas en células asesinas naturales; y Vir Biotechnology (Estados Unidos) enfocada en el desarrollo de inmunoterapias; entre otros miembros. El grupo colaboró con VIB-Ghent University (Bélgica), un instituto de inmunología líder, para publicar el estudio en Science Immunology. En este estudio, los científicos de VIB-Ghent University mapearon la expresión y regulación del receptor Fc para ilustrar cómo el nuevo modelo de ratón podría usarse para modelar mejor la enfermedad humana y coordinaron la publicación del trabajo.

      Una solución única disponible para la comunidad científica

      El modelo genO–hFcγR se basa en un modelo murino previo desarrollado en 2008 por genOway y sus colaboradores científicos, en el que se humanizaron múltiples genes FcγR. Desde su lanzamiento a la comunidad científica en 2024, genO-hFcγR se ha adoptado para impulsar programas preclínicos de compañías biofarmacéuticas y organizaciones sin fines de lucro, incluida la Fundación Gates, como una de sus iniciativas globales de investigación en salud.

      Lea el comunicado de prensa de la Fundación Gates en https://www.genoway.com/news-events/genoway-gates-foundation-2025

      Acerca de genOway

      genOway es una empresa biotecnológica que proporciona modelos y soluciones preclínicos altamente predictivos a compañías biofarmacéuticas, CRO e instituciones académicas para facilitar la transición entre los hallazgos preclínicos y el éxito clínico. Más información en genoway.com.

      Contacto
      Ana REZA
      Gerente de Comunicaciones de Marketing
      [email protected]

      Imagen - https://mma.prnewswire.com/media/2918508/genOway_1.jpg
      Imagen - https://mma.prnewswire.com/media/2918506/genOway_2.jpg
      Logo - https://mma.prnewswire.com/media/2918507/5819376/genOway_Logo.jpg

      Modal title

      Also from this source

      genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model

      genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model

      Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in...

      genOway : révolutionner la prédiction des thérapies à base d'anticorps chez l'humain grâce à un modèle murin unique

      genOway : révolutionner la prédiction des thérapies à base d'anticorps chez l'humain grâce à un modèle murin unique

      Les thérapies par anticorps modifient le traitement du cancer, des maladies inflammatoires et des infections. Cependant, de nombreux médicaments...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Computer & Electronics

      Computer & Electronics

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.